Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | MAP2 | P11137 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | HTR1F | P30939 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28746390 | 0.89 | MCL1 (0.57) | HTR6KDM4EALDH1A1FOLH1MAP2 | |
| SCHEMBL2003146 | 0.87 | KDM4E (0.72) | HTR6KDM4EALDH1A1FOLH1MCL1 | |
| SCHEMBL5279031 | 0.87 | MAP2 (0.57) | HTR6KDM4EALDH1A1FOLH1MAP2 | |
| SCHEMBL9499798 | 0.82 | HTR6 (0.76) | HTR6KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL6430294 | 0.82 | ALDH1A1 (0.57) | HTR6KDM4EALDH1A1FOLH1MAP2 | |
| SCHEMBL4262908 | 0.81 | KDM4E (0.62) | KDM4EALDH1A1FOLH1MAP2EGFR | |
| SCHEMBL4292563 | 0.80 | HTR6 (0.62) | HTR6KDM4EALDH1A1MAP2HTR1A | |
| SCHEMBL1486947 | 0.80 | HTR6 (1.00) | HTR6KDM4EALDH1A1HTR1ADRD2 | |
| SCHEMBL7745979 | 0.79 | KDM4E (0.57) | KDM4EALDH1A1FOLH1MAP2EGFR | |
| SCHEMBL631701 | 0.79 | MAP2 (0.53) | HTR6KDM4EALDH1A1FOLH1MAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228543-A1 | MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | MIDCAP FINANCIAL TRUST, AS AGENT | 2014-08-14 | — | — | US | disclosed |
| EP-0828750-B1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | EC TECHNOLOGY LLC (US) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012154680-A2 | MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | BIOTHERA, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-0828750-A4 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | EC TECHNOLOGY LLC (US) | 2007-11-07 | — | — | EP | disclosed |
| US-5945527-A | REACTING CYTOSINE CONTAINING A LEAVING GROUP ATTACHED TO 5- OR 6-POSTION OF MOLECULE, ISOLATING MODIFIED NUCLEOSIDE; FOR NOVEL FUNGICIDES, VIRICIDES, BACTERICIDES, ANTITUMOR AGENTS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| EP-0828750-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NeXstar Pharmaceuticals, Inc. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038460-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228543-A1 | MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | MANBA, ALG1, MAN2A1 | HTR6 4375/4885KDM4E 2959/4885ALDH1A1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.